A Three-Decade Journey Built on Vision and Impact

Sara entered the medical device field with a clear sense of purpose: to contribute meaningfully to the technologies that improve patient outcomes. In the early stages of her career, she worked on the ground in medical device sales, spending long hours in hospitals, operating rooms, and surgical offices where she developed a granular understanding of both product performance and the needs of clinicians.

These early experiences shaped the foundation of her leadership philosophy. Managing territories, building relationships with surgeons, and navigating high stakes product launches taught her adaptability and strategic thinking. As she progressed into sales management and national leadership positions, Sara increasingly focused on building and mentoring teams, something she describes as the driving force of her professional journey.

Across three decades, she led organizations through major industry shifts, rapidly evolving technology pipelines, and intensifying market headwinds. What set her apart was her ability to create cultures grounded in collaboration and rigorous processes, while maintaining an unwavering focus on continuous improvement. These values not only elevated team performance but also set the stage for sustained market success in some of the industry’s most complex therapeutic areas.

Today, as she leads national sales at Iantrek, Sara views this role as a defining milestone, an opportunity to help shape the future of ophthalmology through innovative, life-changing surgical solutions.

A Legacy of High-Performing Teams and Transformational Results

Among her many achievements, Sara is most proud of the sales organizations she has built – teams that not only surpassed targets but also helped redefine standards in the medical device landscape. One landmark accomplishment was leading the nationwide launch of a groundbreaking neuromodulation surgical solution in a high‑growth start‑up, directly competing against a major strategic where she had previously built her career. Operating without the safety net of big-company infrastructure, she was tasked with accelerating market adoption while simultaneously standing up the engine behind it: field training, surgeon education pathways, branding, messaging, and robust comprehensive product support. Through open dialogue, radical transparency, and disciplined, data‑driven coaching, she rallied and elevated her team, outpacing expectations and driving rapid adoption across priority markets despite formidable competitive pressure.

Watching many of her team members rise into leadership roles remains one of her greatest professional rewards. For Sara, mentorship is not a responsibility, it’s an investment in the future of an industry built on trust, clinical rigor, and meaningful innovation.”​​

Every major product launch, partnership initiative, and talent development milestone reinforced a core belief she carries today: lasting success is built through disciplined execution and empowering people to reach their fullest potential. This guiding principle continues to shape her work at Iantrek as the company scales and redefines what’s possible in micro-interventional ophthalmic surgery. The team under Sara’s leadership will be advancing next-generation technologies to transform total-outflow enhancement in glaucoma.

Shaping the Future of Glaucoma Care With Iantrek

The surgical glaucoma landscape has entered a pivotal moment as clinicians are increasingly encountering patients whose prior minimally invasive glaucoma surgery (MIGS) are no longer maintaining adequate control. Historically, these patients have faced a narrow set of options between escalating medications and transitioning to more invasive filtering procedures, creating a substantial therapeutic gap. More than 3 million eyes in the United States now fall into this segment, with hundreds of thousands added annually as MIGS volumes continue to rise.

Iantrek was founded to address this need by enabling surgical access to the second of the eye’s two natural outflow pathways – an anatomic route that previously lacked a practical, reproducible method for intervention. As MIGS have become standard of care, providers have been limited to surgically addressing only one of the eye’s outflow systems, reducing how effectively care can be customized for patients with progressive disease. Through its proprietary Allo™ platform, Iantrek has modernized a long-standing surgical concept using homologous, bio-tissue for controlled access without hardware or permanent implants.

The company’s flagship product, AlloFlo™ Uveo, is a minimally manipulated allogeneic Bio-Spacer tailored to reinforce a surgical opening into this second outflow pathway, offering surgeons a new minimally invasive option for patients who are no longer well controlled following prior MIGS, yet are not candidates for filtering surgery. Early clinical adoption underscores both the scale of the opportunity and the practical value of adding a new choice to the interventional glaucoma continuum.

As interest grows, Iantrek is expanding its national commercial infrastructure to match growing demand and strengthen collaboration with leading surgeons. With the Allo™ platform and AlloFlo Uveo, Iantrek is positioned to lead the next chapter of interventional glaucoma.

A Message to Future Leaders

Reflecting on her journey, Sara offers clear, grounded advice for those aspiring to lead in the medical device industry: understand your purpose, invest in people, and embrace the challenges that shape growth.

“Leadership in this industry is both a privilege and a responsibility” she emphasizes. Success is not merely defined by product performance or quotas, it is fueled by commitment to the people who make progress possible. She encourages young professionals to build structured processes, cultivate transparency, and remain open to learning at every stage.

For Sara, true leadership means empowering teams, navigating uncertainty with confidence, and maintaining high standards rooted in respect and accountability. These principles not only drive business success but also create meaningful, lasting impact on the clinicians and patients whose lives are touched by medical innovation.